FLT3 and acute myeloid leukemia: Despite encouraging preliminary results [44], the phase 3 LACEWING trial of the FLT3 inhibitor Gilteritinib (Xospata®, Astellas, Tokyo, Japan) plus Azacitidine versus Azacitidine alone in patients with newly diagnosed FLT3 mutation-positive AML who were ineligible for intensive induction chemotherapy did not meet its primary endpoint of overall survival (OS) at a planned interim analysis, according to Astellas Pharma, the developer of the agent.